ArticleCancer immunology, immunotherapy : CII1995
Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.
Article in Cancer immunology, immunotherapy : CII, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- Case Report: IL-6 suppression: a potential strategy for mitigating severe immune-related adverse events in nivolumab and ipilimumab therapy for malignant pleural mesothelioma.Frontiers in oncology · 2025Article
- Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.Journal of translational medicine · 2024Review
- Review
- CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.Cancers · 2021Article
- Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.Oncotarget · 2018Article
- Serum mesothelin and other biomarkers: what have we learned in the last decade?Journal of thoracic disease · 2018Review
- Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.Scientific reports · 2016Article
- The role of interleukin-6 in malignant mesothelioma.Translational lung cancer research · 2015Review
- Cancer as a Proinflammatory Environment: Metastasis and Cachexia.Mediators of inflammation · 2015Review
- Advances in malignant peritoneal mesothelioma.International journal of colorectal disease · 2015Review
- The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.Journal of immunology research · 2014Review
- Inflammation in malignant mesothelioma - friend or foe?Annals of cardiothoracic surgery · 2012Article
- Kinetics of host cell recruitment during dissemination of diffuse malignant peritoneal mesothelioma.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2010Article
- Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.Journal of biomedicine & biotechnology · 2010Article
- Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma.Cancer gene therapy · 2003Article
- Control of cell cycle progression in human mesothelioma cells treated with gamma interferon.Oncogene · 2001Article
- Peritoneal mesothelioma.Current treatment options in oncology · 2000Review
- Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.British journal of cancer · 1998Article
- The pathologies of bovine viral diarrhea virus infection. A window on the pathogenesis.The Veterinary clinics of North America. Food animal practice · 1995Review
- Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A role for interleukin-6 (IL-6) in malignant mesothelioma has been suggested by the clinically presenting symptoms of mesothelioma patients, which include fever, weight loss and thrombocytosis. A murine model of malignant mesothelioma was therefore used to examine the potential role of IL-6 in this cancer type and whether the effect of interferon alpha (IFN alpha) therapy on mesothelioma might be mediated, in part, by regulating IL-6 levels and/or IL-6-induced pathobiology. A panel of human and murine mesothelioma cell lines was assayed for endogenous IL-6 production in a bioassay, and for IL-6-mRNA expression. Four out of 5 human and 5 out of 15 murine mesothelioma cell lines produced moderate to high levels of bioactive IL-6 in vitro. This result was corroborated by mRNA detection. One of the representative murine cell lines, AB22, was chosen for further in vivo studies in the murine mesothelioma model. In AB22-inoculated mice detectable serum IL-6 levels were found to precede macroscopically detectable tumour growth, clinical signs (cachexia, abdominal distension, diarrhoea) and changes in the peripheral lymphoid organs (cell depletion and functional depression). Treatment with anti-IL-6 antibody curtailed the clinical symptoms (P < 0.001), as did treatment with recombinant human (rhu) IFN alpha (P < 0.001). Neither anti-IL-6 antibody nor rhuIFN alpha had a direct growth-inhibitory effect on the AB22 mesothelioma cell line in vitro, however, in vivo rhuIFN alpha treatment of mice inoculated with AB22 cells attenuated both IL-6 mRNA expression in the tumours and serum IL-6 levels, ameliorated the depression of lymphocyte activities, and enhanced the number of tumour-infiltrating lymphocytes and macrophages. On the basis of these results it is suggested that IL-6 mediates some of these effects, directly or indirectly, and that a combination therapy of rhuIFN alpha and anti-IL-6 antibody may be an improved palliative treatment for patients with malignant mesothelioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.